EarningsQ2 2026 Earnings Report
TLPPF Q2 2026 EPS Results
Actual EPS$0.17
Consensus EPS$0.02
Beat/MissBeat by +$0.15
One Year Ago EPS$0.01
TLPPF Q2 2026 Revenue Results
Actual Revenue$473.68M
Expected Revenue$247.00M
Beat/MissBeat by +$226.68M
YoY Revenue Growth+10.42%
Earnings Announcement Details
QuarterQ2 2026
Date08/19/2026
TimeAfter Close
Conference CallWednesday, August 19, 2026
TLPPF Upcoming Earnings
Telix Pharmaceuticals's next earnings date is estimated for February 19, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
TLPPF Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted multiple strong commercial and clinical positives: double‑digit revenue growth (H1 revenue $477M, +22% YoY), robust Precision Medicine momentum (~$390M, +27% YoY), improving margins, a solid cash position ($252M), near-term regulatory catalysts (Pixclara PDUFA on 11 Sep) and advancement of Phase III therapeutic programs and the BiPASS study. Offsetting these are material regulatory uncertainties (notably the Zircaix CRL and required resubmission to address third‑party manufacturing deficiencies), timing risk for European approvals, higher near‑term R&D spend ($230M–$270M guidance) and competitive/reimbursement dynamics. Overall, the highlights — including strong commercial execution, product launches, pipeline progress and strategic partnerships — materially outweigh the lowlights, though execution against regulatory milestones and funding of increased R&D spend remain key watch items.Company Guidance
Strong Top-Line Growth
Reported group revenue of $477 million for H1 2026, up 22% year-on-year, driven by robust commercial execution in the Precision Medicine franchise.
Precision Medicine Momentum
Precision Medicine sales ~ $390 million, up 27% year-on-year; Q2 PSMA revenue was $202 million (+9% quarter-on-quarter), following Q1 $186 million (+16% quarter-on-quarter). Management expects Precision Medicine growth in excess of 20% year-on-year for the full year.
Profitability and Cash Position
Net profit after tax rose to $38 million. The company increased cash balance to $252 million following a convertible bonds refinance. Management emphasized strong cash generation and reinvestment into growth.
Improved Margins and Cost Discipline
Precision Medicine gross margin improved to 65% (+1% year-on-year); consolidated gross margin improved to 55% (+2% year-on-year). Operating expenditure was disciplined, reducing by 1% as a percentage of sales.
Multiple EBITDA Measures Showing Improvement
Management reported EBITDA improved 146% year-on-year to $52 million and also referenced EBITDA growth of 26% year-on-year to $132 million (two EBITDA measures were presented in the call, reflecting different reporting lenses).
Regulatory and Near-Term Launch Catalysts
Pixclara U.S. PDUFA date assigned for 11 September 2026; Pixlumi submission completed in Europe. These near-term regulatory milestones position the company for upcoming product launches.
Clinical & Therapeutic Progress
Three Phase III therapeutic candidates advanced (including TLX591 in prostate cancer with FDA alignment on Part 2) and BiPASS biopsy Phase III close to targeted enrollment; ProstACT Part 2 aligned with FDA and dosing continuing in multiple countries.
Strategic Collaboration and Manufacturing Buildout
Entered collaboration with Regeneron to accelerate next-gen candidates (focus on alpha therapies). Acquired/expanded manufacturing and distribution capabilities including RLS integration, new translational research site in Melbourne, and CapEx investments at Seneffe, Yokohama and RLS to support therapeutic delivery.
Commercial Execution and Market Share Gains
Two-product PSMA strategy (Illuccix and Gozellix) reported 16 consecutive quarters of increased unit and revenue share; strong physician uptake and international launches now in ~24 countries, with China NDA submitted and Japan registration study enrollment completed (>100 patients).
Guidance Maintained with Upside Potential
Full-year revenue guidance maintained at $950 million to $970 million with management indicating expectations to land at the upper end of the range. R&D guidance updated to $230 million–$270 million reflecting deliberate pipeline investment.
TLPPF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed